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Vezf1 is an early development gene that encodes a zinc finger transcription factor. In the developing embryo, Vezf1 is expressed in the yolk
sac mesoderm and the endothelium of the developing vasculature and, in addition, in mesodermal and neuronal tissues. Targeted inactivation
of Vezf1 in mice reveals that it acts in a closely regulated, dose-dependent fashion on the development of the blood vascular and lymphatic
system. Homozygous mutant embryos display vascular remodeling defects and loss of vascular integrity leading to localized hemorrhaging.
Ultrastructural analysis shows defective endothelial cell adhesion and tight junction formation in the mutant vessels. Moreover, in
heterozygous embryos, haploinsufficiency is observed that is characterized by lymphatic hypervascularization associated with hemorrhaging
and edema in the jugular region; a phenotype reminiscent of the human congenital lymphatic malformation syndrome cystic hygroma.
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Mammals have two structurally different circulatory
systems, the closed blood vasculature and the open
lymphatic system, that are functionally connected and act
in concert to maintain tissue homeostasis. The blood0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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5 Present address: Biogen Inc., Cambridge, MA 02142, USA.vascular system, consisting of arteries, capillaries, and
veins, efficiently carries nutrients, gases, and waste products
to and from distant actively metabolizing tissues. The
lymphatic system regulates tissue fluid balance by returning
interstitial fluid and macromolecules from the tissue spaces
of most organs back into the venous circulation and serves
as a conduit for trafficking immune cells, thus complement-
ing the function of the blood vascular system.
During embryonic development, the blood vascular
system is formed via two distinct processes. Vasculogenesis
describes the initial differentiation of mesodermally derived
endothelial precursor cells, angioblasts, and their coales-
cence into a primitive vascular network. Angiogenesis refers
to the subsequent growth, remodeling, and maturation
processes of the primary vascular plexus to give rise to
the mature blood vasculature (Carmeliet, 2000; Risau,
1997). The lymphatic system develops through sprouting
from the venous system, a process that becomes first83 (2005) 140 – 156
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midgestation (Wigle and Oliver, 1999).
The vascular endothelial growth factor (VEGF) signal-
ing pathway plays a critical role in the regulation of both
blood vascular and lymphatic development. VEGF-A
signaling, through binding to its blood endothelial cell-
specific receptors VEGFR-1 and VEGFR-2, is essential
for the early stages of blood vascular development and
the initiation of vascular sprouting (Carmeliet et al.,
1996a; Ferrara et al., 1996). In contrast, selective
activation of VEGFR-3 signaling using receptor-specific
mutants of VEGF-C and VEGF-D induces lymphangio-
genesis in the skin of transgenic mice (Veikkola et al.,
2001). The importance of VEGFR-3 signaling for
lymphatic development is underscored by the findings
that lymphatic vessels in VegfC-null embryos fail to
sprout (Karkkainen et al., 2004), overexpression of
soluble VEGFR-3 leads to inhibition of lymphangio-
genesis (Makinen et al., 2001), and mutations in the
tyrosine kinase domain of VEGFR-3 are linked to human
hereditary primary lymphedema (Karkkainen et al., 2000).
Recently, angiopoietin signaling, in addition to its well-
established function during blood vascular remodeling and
vessel stabilization (Gale and Yancopoulos, 1999), has
also been implicated in the regulation of lymphatic
development (Gale et al., 2002).
At the level of transcriptional regulation, Prox1 activity is
required for maintaining lymphatic endothelial cell sprout-
ing, and loss of Prox1 function results in arrested lymphatic
development without affecting blood vessel formation
(Wigle et al., 1999, 2002). Moreover, misexpression of
Prox1 in blood endothelial cells confers a lymphatic
endothelial phenotype, indicating that Prox1 is a master
regulator of the lymphatic endothelial cell fate (Hong et al.,
2002; Petrova et al., 2002). Using gene inactivation
approaches, several transcription factors have been impli-
cated in blood vascular development (for review, see
Oettgen, 2001). For instance, genetic ablation of the
bHLH-PAS protein hypoxia inducible factor 1a (HIF-1a)
leads to defective yolk sac and cephalic vascularization (Iyer
et al., 1998; Ryan et al., 1998), while the zinc finger lung
Kru¨ppel-like factor (LKLF) is required for vascular smooth
muscle cell and pericyte recruitment during vessel stabiliza-
tion (Kuo et al., 1997).
Vascular endothelial zinc finger 1 (Vezf1) was originally
identified as a gene specifically expressed in vascular
endothelial cells during early embryonic development
(Xiong et al., 1999), although our subsequent analysis
indicated expression in mesodermal and neuronal tissues as
well (Lemons et al., 2005). Vezf1 encodes a 518 amino
acid nuclear protein that contains six zinc finger motifs of
the C2H2 (Kru¨ppel-like)-type and a proline-rich transcrip-
tional transactivation domain at its C-terminus (Lemons et
al., 2005). Consistent with the hypothesis that VEZF1 is a
bona fide transcription factor, the human ortholog
ZNF161/DB1 has been shown to selectively transactivatethe endothelial cell-specific human endothelin-1 promoter
in vitro (Aitsebaomo et al., 2001). In addition, Vezf1 has
been implicated in the regulation of endothelial cell
proliferation, migration, and network formation in vitro
(Miyashita et al., 2004). To investigate the role of Vezf1 in
vivo, we have generated a null allele by gene targeting.
Here we report that inactivation of Vezf1 results in lethality
caused by angiogenic remodeling defects and loss of
vascular integrity in homozygous mutant embryos. Fur-
thermore, loss of a single Vezf1 allele leads to an incom-
pletely penetrant phenotype characterized by lymphatic
hypervascularization that is associated with hemorrhaging
and edema in the jugular region. This haploinsufficient
phenotype is reminiscent of the human congenital malfor-
mation syndrome, cystic hygroma (Gallagher et al., 1999).
Our studies show that Vezf1 is a crucial regulator of
blood vessel and lymphatic development that acts in a
tightly regulated dose-dependent fashion during embryonic
development.Materials and methods
Construction of the Vezf1 targeting construct and ES cell
manipulations
A 5VVezf1 cDNA fragment (nt 3–776 of the published
mouse Vezf1 cDNA sequence, GenBank accession no.
AF104410; Xiong et al., 1999) was used as a probe to
screen a mouse 129/Sv lambda genomic library (provided
by K. Andrikopoulous and F. Ramirez, Mount Sinai School
of Medicine). One positive phage clone contained the first
and second exon separated by 5 kb of intronic sequence and
15 kb of genomic sequence upstream of exon 1. For
construction of the targeting vector, an 8-kb EcoRV/XhoI
fragment containing the first exon, 6 kb of upstream
genomic sequences and 2 kb of 3V intronic sequence, was
subcloned into pBluescriptIISK (Stratagene). A 390-bp
EagI fragment including the ATG translation initiation
codon was replaced with an IRES-lacZgt1.2neo cassette
(Wang and Lufkin, 2000) via NotI linkers. Subsequent
analysis of the Vezf1 promoter revealed that the deletion
included 91 bp upstream of the transcriptional start site,
resulting in a non-functional lacZ allele.
R1 ES cells (Nagy and Rossant, 1993) were maintained
in DMEM (high glucose) containing 15% heat-inactivated
fetal calf serum (FCS), 0.1 mM h-mercaptoethanol, 20 mM
HEPES, pH 7.3, 0.1 mM non-essential amino acids, and
1000 U/ml LIF on g-irradiated primary MEFs as a feeder
layer. The targeting vector was linearized with XhoI and
introduced into R1 cells by electroporation (400 V, 125 AF;
Bio-Rad Gene Pulser). ES cell clones were selected at G418
concentrations of 200–350 Ag/ml for 10 days. ES cell
clones homozygous for the targeted Vezf1 allele were
obtained by hyperselection (Mortensen et al., 1992) at
concentrations between 400 and 1000 Ag/ml of G418 for 14
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alleles (V2, V74, V86) were identified by Southern blot
analysis of BamHI-digested genomic DNA using a [a-32P]-
dCTP-labeled 5Vgenomic fragment (EcoRV–EcoRV frag-
ment of 1-kb length) and a 3VcDNA fragment correspond-
ing to the second exon (BamHI–PstI of 500-bp length) as
probes. ES cells were induced to differentiate in suspension
cultures into embryoid bodies as described previously
(Leahy et al., 1999).
Northern analysis
Total RNA was prepared from ES cells and embryoid
bodies using a RNeasy Mini Kit (Qiagen). RNA (10 Ag
each) was analyzed on Northern blots as described (Xiong et
al., 1999) using a [a-32P]-dCTP-labeled Vezf1 cDNA
fragment (nucleotides 3–776) as a probe. To control for
RNA loading, filters were stripped and hybridized with
[a-32P]-dCTP-labeled mouse GAPDH cDNA plasmid.
Generation of Vezf1 KO mice and genotyping
Chimeric mice were generated by injection of Vezf1+/
ES cells from clones V2, V74, and V86 into C57BL/6
blastocysts (performed by the Transgenic Core Facility at
Mount Sinai School of Medicine). Mice at weaning age and
staged embryos from E14.5 to birth (the morning of the
vaginal plug was counted as day 0.5 post-coitum) were
genotyped by Southern blot analysis of BamHI-digested tail
or yolk sac DNA, respectively. A 500-bp fragment from
exon 2 was used as a 3V flanking probe for Southern blot
analysis (see above). Staged embryos from E8.5 to E13.5
were genotyped by genomic PCR. Primers for the wild type
Vezf1 allele are: 5V (5V-GCGTCCCGGAGGTTACCGAA-
GTGG-3V) and 3V (5V-GGAACAGGAACGCGGTCCAGT-
TGG-3V), yielding an amplification product of 150 bp;
primers for the targeted allele are: 5V (5V-TTTCTCTG-
GGCCGCGGGGTGGT-3V) and 3V (5V-GCGGGGATCT-
CATGCTGGAGTT-3V), yielding a 300-bp amplification
product.
Western blot analysis and antibodies
E12.5 embryos from heterozygous intercrosses were
homogenized in 500 Al RIPA buffer each. 40-Ag samples
of denatured protein were resolved on 10% SDS gels and
transferred to polyvinylidene difluoride (PVDF) membranes
(Millipore Corporation, Bedford, MA) using standard
procedures. Anti-VEZF antibody against the N-terminal
peptide AIGIKKEKPKTSFV (1 Ag/ml, Multiple Peptide
Systems, San Diego; Lemons et al., 2005) and horseradish
peroxidase-conjugated anti-rabbit IgG (Amersham Bio-
sciences, Piscataway, NJ) were used. Specific bands were
detected with ECL Plus Western Blot Reagent (Amersham).
To control for loading, blots were stripped and reprobed
with anti-h-tubulin antibody (1:2000 dilution).Whole-mount PECAM-1 staining of embryos and yolk sacs
Staged embryos from the fifth backcross generation
(F5) were fixed in 4% paraformaldehyde (PFA)/PBS
overnight at +4-C, dehydrated through a methanol series,
and stored in 100% methanol at 20-C. Embryos were
bleached in 6% hydrogen peroxide/methanol for 1 h at
room temperature and rehydrated through a methanol
series to PBS/0.1% Tween 20 (PBST). After blocking in
3% instant skim milk/PBST (PBSMT) twice for 1 h, the
embryos were incubated overnight at +4-C with a
monoclonal rat anti-mouse CD31 (PECAM-1) antibody
(1:50 dilution in PBMST; MEC13.3, Pharmingen) (Krebs
et al., 2000). Embryos were washed with PBSMT five
times for 1 h at +4-C and incubated with peroxidase-
conjugated donkey anti-rat secondary antibody (Jackson
Immunoresearch) overnight at +4-C in PBST. Peroxidase
reaction was visualized with DAB/hydrogen peroxide.
Yolk sacs were embedded in paraffin, thin-sectioned, and
counterstained with Nuclear Fast Red.
Histology and immunohistochemistry
Litters from timed (Vezf1+/  Vezf1+/) matings were
recovered between E8.5 and birth. Yolk sacs were isolated
for genotyping and embryos were photographed in ice-cold
PBS under a Nikon SMZ-U stereomicroscope with a 35-mm
camera. After overnight fixation in 4% PFA/PBS at +4-C,
the embryos were dehydrated and embedded in paraffin.
Serial sections (5 Am) were deparaffinized, rehydrated, and
stained with hematoxylin and eosin (H&E). Immuno-
histochemistry on paraffin sections of embryos was per-
formed according to standard protocols. The following
antibodies were used: mouse anti-SMa-actin/HRP (DAKO,
1:100), rat anti-PECAM-1 (BD Pharmingen, 1:100), rat
anti-mouse VEGFR-3 (kindly provided by H. Kubo and K.
Alitalo) (Kubo et al., 2000), rabbit anti-mouse LYVE-1
antibody (kindly provided by D. Jackson) (Prevo et al.,
2001). All antibody-stained sections were counterstained
with hematoxylin. Photomicrographs were taken under a
Zeiss Axioplan2 microscope with a digital Zeiss AxioCam
color camera.
For immunofluorescence studies, the following anti-
bodies were used: rabbit anti-Prox1 (1:100 dilution;
kindly provided by G. Oliver), rat anti-mouse CD31
(1:200; BD Pharmingen), rabbit anti-collagen IV (1:200;
Chemicon), rabbit anti-ZO-1 (1:100; Zymed), and rat
anti-mouse VE-cadherin (1:20; BD Pharmingen). Staged
embryos were fixed overnight at 4-C in 4% PFA/PBS,
cryoprotected in 30% sucrose/PBS, and embedded in
OCT (TissueTek). Ten-micron cryostat sections were
stained according to standard protocols. Primary anti-
bodies were incubated overnight at 4-C, and staining was
revealed with Alexa488-labelled rabbit anti-rat IgG and
Cy3-labelled goat anti-rabbit IgG, respectively. Control
sections were incubated with nonspecific rabbit and rat
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mounted with fluorescent mounting medium (DAKO),
examined under an epifluorescence (Zeiss Axioplan2) or
under a confocal microscope (Bio-Rad MRC-1024),
respectively, and photographed.
Transmission electron microscopy
Heads of E9.5 embryos were placed overnight in ice-cold
fixative (4% paraformaldehyde, 1.5% glutaraldehyde in 0.1
M Na cacodylate buffer). Preparation of samples and
analysis by electron microscopy were performed by the
Microscopy Core Facility at The Scripps Research Institute.
Following standard procedures, specimens were examined
under a Philips CM100 electron microscope (FEI, Hill-
sbrough OR), and images were documented using Kodak
SO163 EM film.
Vessel morphometry
PECAM-1-stained sections of E13.5 wild type and
heterozygous mutant embryos were counterstained with
hematoxylin. Quantitative morphometric analysis was
performed essentially as described (Pozzi et al., 2000).
Briefly, sections were imaged with a digital camera
(Pixera, Los Gatos, CA). Images were processed by
using Scion Image software (Frederick, MD). PECAM-1-
positive structures in the neck region of embryos were
automatically counted, and their area was measured
(values represent area occupied by PECAM-1 positive
structures per microscopic field, expressed in percent).
Differences in vascularity (number of and area occupied
by PECAM-1-positive structures per embryo microscopic
field) were determined for each section. A total of 3
heterozygous mutant and wild type embryos each were
analyzed.
Cultivation of megakaryocytes from embryonic livers
Fetal livers from E12.5 embryos were isolated and
placed into low-glucose DMEM supplemented with 10%
FCS and 10 ng/ml mouse TPO (Lecine et al., 1998). Liver
cells were dissociated by drawing them subsequently
through 20-g and 25-g needles. Cells from one liver were
seeded into a 6-well dish and incubated at 37-C in 5%
CO2. After 6 days of culture, cells were visually examined
under the microscope, harvested, and stained with Wright–
Giemsa solution.
Gene expression analysis
Total RNAwas isolated from E10.5 embryos using Trizol
(Life Technologies) and treated with DNaseI (Life Tech-
nologies) according to the manufacturer’s instructions. Total
RNA (2 Ag) was reverse transcribed using random hexamers
with the Superscript First Strand Synthesis System (LifeTechnologies) according to the manufacturer’s instructions.
PCR was performed using 1 Al of the reverse transcriptase
reaction in a volume of 50-Al using Hotstar Taq poly-
merase (Qiagen). The PCR conditions were as follows:
initial denaturation at 95-C for 10 min followed by up to
35 cycles of denaturation at 95-C (1 min), annealing at 58-C
(1 min), and extension at 72-C (1 min). 5-Al aliquots
were taken after 25, 30, and 35 cycles and amplified
PCR products were analyzed by electrophoresis on a 2%
agarose gel. PCR primer pairs were as follows: Flk-1: 5V-
TCTGTGGTTCTGCGTGGAGA-3V, 5V-GTATCATTTCC-
AACCACCCT-3V; Flt-1 : 5V-TGT-GGAGAAACTTG-
GTGACCT-3V, 5V-TGGAGAACAGCAGGACTCCTT-3V;
Flt-4 : 5V-CACCGAAGC-AGACGCTGATGAT-3V, 5V-
AGCTGCTGTCTGCGAAGAAG-3V; VEGF-A : 5V-
GTAACGATG-AAGCCCTGGAGTG-3V, 5V-TGA-
GAGGTCTGGTTCCCGAAAC-3V; VEGF-C : 5V-AA-
ATGTACA -AGTGCCAGCTGCGGAA - 3 V, 5 V-
GGCATCGGCACATGTAGTTATTCCA-3V; VEGF-D :
5V-ACGA-TCTGAACAACAGATCCGAGCA-3V,
5V-TCTGGGGTCTGAATGGATCTTCTGA-3V; Tie1: 5V-
TC-TTTGCTGCTCCCCACTCT-3V, 5V-ACACACCAT-
TCGCCATCAT-3V; Tie2 : 5V-CCTTCCTAC-CTG-
CTACTTTA-3V,5V-CCACTACACCTTTCTTTACA-
3V; Ang1 :5V-AAGGGAGGAAAAAGAGA-AGAA-
GAG-3V, 5V-GTTAGCATGA-GAGCGCATTTG-3V;
Ang2 : 5V-TGCCTACACTACCAGA-AGAAC-3V, 5V-T-
ATTTACTGCTGAACTCCCAC-3V; Notch1 : 5V-
TGCCTGAATGGAGGTAG-GTGCGAA-3V, 5V-G-
CACAGCGATAGGAGCCGATCTCA-3V; Notch4 : 5V-
CCAAGAGATTCCCTT-AAACTCGG-3V, 5V-CCAGA-
GTTTAGGGATTCTCG-3V; Dll4: 5V-GACTGAGCTACTC-
TTAC-CGGGTCA-3V, 5V-CTTACAGCTGCCACCATTTC-
GACA-3V;Eph r i nB2 : 5V-CTGTGCCAGACCAG-
ACCAAGA-3V,5V-CAGCAGAACTTGCATCTTGTC-3V;
EphB4 : 5V-CAGGTGGTCAGCGCTC-TGGAC-3V,5V-
ATCTGCCACGGTGGTGAGTC-3V; Prox-1 : 5V-TTT-
CAATGCCATCATCGCG-GGCAAAG-3V, 5V-TCACGTG-
CACTTTACACAGGCTGACA-3V; podoplanin: 5V-AC-
CCTGGTTGG-AATCATAGTTGGCGT-3V, 5V-AG-
GGTGAACCCATGGTTACAGTTGCT-3V;Tbx1 :5V-
GTTGCAG-CCTTCGCAGCCAGCA-3V, 5V-TAGT-
GTACTCGGCCAGGTGTAGCA-3V; LKLF: 5V-CCAC-
ACATA-CTTGCAGCTACAC-3V,5V-CCATCGTCTCCC-
TTATAGAAATA-3V; EDG-1 : 5V-TAGCAGCTA-
TGGTGTCCACTAG-3V, 5V-GATCCTGCAGTAGAG-
GATGGC-3V; Endoglin: 5V-TACTCATGTCC-CTGATC-
CAGCC-3V,5V-GTCGATGCACTGTACCTTTTTCC-
3V; VE-cadherin : 5V-GG-ATGCAGA-GGCTCACA-
GAG-3V, 5V-CTGGCGGTTCACGTTGGACT-3V; ET-
1 : 5V-TGTCTT-GGGAGCCG-AACTCA-3V,5V-GC-
TCGGTTGTGCGTCAACTTCTGG-3V; Vezf1 : 5V-
GTCTCATGAAGGAGGCA-TCACCA-3V, 5V-ACATG-
TTTTACATGACAGCTTAGGT-3V; b-actin :5V-GTG-
GGCCGCTCTAGG-CACCAA-3V,5V-CTCTTTGATGT-
CACGCACGATTTC-3V.
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Targeted disruption of the Vezf1 gene in mouse embryonic
stem cells
A 20-kb genomic Vezf1 fragment was isolated that
contained the first and second coding exons of 153- and
695-bp length, respectively, the first intron of 5-kb length,
and 15 kb of genomic sequence upstream of exon 1. A
targeting vector was constructed that replaced exon 1 and
the proximal part of the first intron with a promoter-less
IRES-lacZ gene and a neo expression cassette (Fig. 1A).Fig. 1. Targeted inactivation of the Vezf1 gene. (A) Targeting strategy. Exons are
DNA, and the proximal part of the first intron were replaced with an IRES-lacZ-ne
of homology between the endogenous locus (top) and the targeting vector (middle
bottom. Locations of probes for Southern analysis corresponding to 5Vand 3Vflank
X, XhoI. (B) Southern blot analysis of three correctly targeted ES cell clones. 1
flanking probe shown in (A). Sizes of hybridizing fragments are indicated. Genotyp
targeted Vezf1+/ ES cell clones (#2, 74, 86) were identified. (C) Southern blot
hyperselection protocol. Experimental procedures are identical to those in B. One
RNA from ES cells and day 6 embryoid bodies using a Vezf1 cDNA fragment (nuc
probe to control for loading. Genotypes are indicated at the top of each lane. No
bodies. (E) Western blot analysis of total cell extracts from E12.5 embryos (geno
endothelioma cells (EOMA) was loaded as a control. The filter was stripped andThe construct was introduced into R1 ES cells, and three
independent clones out of 96 G418-resistant clones ana-
lyzed contained the correctly targeted allele (Fig. 1B). An
ES cell clone that carried the introduced mutation in both
alleles (Fig. 1C) was obtained by G418 hyperselection
(Mortensen et al., 1992). Using a probe corresponding to the
second coding exon, low levels of Vezf1 transcripts were
detected by Northern analysis in undifferentiated wild type
R1 cells, and high levels in day 6 embryoid bodies derived
from wild type R1 cells (Fig. 1D), consistent with previous
studies (Xiong et al., 1999). In contrast, Vezf1 mRNA was
reduced by about half in embryoid bodies derived fromrepresented as numbered boxes. The first exon, 91 bp of upstream genomic
o expression cassette by homologous recombination in R1 ES cells. Regions
) are indicated by lines. The structure of the targeted allele is shown on the
ing regions are indicated by bars. B, BamHI; E, EagI; E5, EcoRV; N, NotI;
0-Ag genomic DNA was digested with BamHI and hybridized with the 5V
es of ES cell clones are indicated at the top of each lane. Three independent
analysis of DNA isolated from individual ES cell clones subjected G418
Vezf1/ clone (lane 2) was recovered. (D) Northern blot analysis of total
leotides 3–776) as a probe. The filter was reprobed with a GAPDH-specific
Vezf1-specific transcript was detected in Vezf1/ ES cells and embryoid
types are indicated) using VEZF1-specific antibodies. Nuclear extract from
reprobed with an anti-h-tubulin antibody to control for equal loading.
Table 1
Genotypes from Vezf1+/  Vezf1+/ intercrosses in C57BL/6 backgrounda
Development
stage
No. of
embryos
+/+ +/b /b Frequency
of /
embryos (%)
E9.5 97 27 52 18 (8) 19
E10.5 47 14 28 (2) 5 (2) 11
E11.5 79 23 45 (2) 11 (5) 14
E12.5 79 23 46 (10) 10 (4) 13
E13.5 45 7 32 (7) 6 (2) 13
E14.5 13 5 7 1 8
E16.5 11 2 8 1 (1) 9
P0 21 9 13 0 0
a Embryos from Vezf1+/  Vezf1+/ intercrosses (F5 to F10 backcross
generation in the C57BL/6 background) were analyzed. Embryos from
embryonic stages E9.5 to E16.5 were genotyped by performing PCR on
genomic yolk sac DNA with primer pairs specific for the wild type and
targeted allele. DNA from tail clips was used for genotyping of newborn
pubs (P0).
b Numbers in parentheses represent embryos with vascular abnormalities
and hemorrhaging.
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Vezf1/ ES cells or in embryoid bodies derived from this
clone (Fig. 1D). Furthermore, Vezf1 mRNA could not be
detected in KO embryos by RT-PCR using primer pairs
spanning the entire coding sequence (data not shown),
indicating that the targeting event resulted in a null
mutation. Consistent with this, VEZF1 protein expression
was reduced in heterozygous, and undetectable in homo-
zygous mutant embryos (Fig. 1E). All three ES cell clones
transmitted the targeted allele through the germ line, and
mice from the three lines displayed identical mutant
phenotypes.Fig. 2. Vascular defects in E9.5 Vezf1/ embryos. (A and D) Photomicrographs
displayed hemorrhaging in the head, the trunk, and the pericardial cavity. (B an
in head, neck, and dorsal part of intersomitic vessels of Vezf1/ embryos (B)
The arrow indicates absence of the second aortic arch artery in the Vezf1/ e
embryo (C) displayed hemorrhaging in the head and the pericardial cavity (arro
(F) Wild type control.Disruption of Vezf1 results in vascular defects and lethality
in homozygous and heterozygous embryos
The Vezf1 mutation was examined in the C57BL/6
background. Heterozygous Vezf1+/ mice were viable,
fertile, and appeared phenotypically indistinguishable from
their wild type littermates. In contrast, no viable Vezf1/
offspring were obtained (Table 1). Embryonic death and
intraembryonic hemorrhage of the Vezf1 KO phenotype
became apparent at E9.5 (Table 1, Fig. 2A). Hemorrhaging,
retarded, or resorbed Vezf1/ embryos at sub-Mendelian
ratios were found up to E16.5 (Table 1, Fig. 4A). Beginning
at E12.5, about 20% of heterozygous embryos (10 out of 46;
22%) displayed localized edema and hemorrhaging in the
back and neck (Table 1, Fig. 8A). At E13.5, these mutant
Vezf1+/ embryos (7 out of 32; 22%) appeared bloated,
displaying massive edema, hemorrhaging, and signs of
tissue necrosis in the back and neck (Table 1, Fig. 8C).
Hemorrhaging Vezf1+/ embryos were not detected at later
embryonic stages and presumably died before E14.5.
Consistent with this notion, heterozygous offspring (total
296) from backcrosses into the C57Bl/6 strain were
recovered at a ratio of 41% Vezf1+/: 59% wild type.
In a mixed and outbred genetic background, a less severe
and less penetrant phenotype was observed (Table 2),
suggesting contribution of yet unknown strain-specific
segregating modifier genes. Whereas no viable Vezf1/
offspring were recovered at weaning age, stillborn P0
Vezf1/ pups displaying intraembryonic hemorrhage were
detected at a ratio of ¨60% of the expected Mendelian
frequency. Vezf1/ embryos appeared phenotypically
normal up to E11.5 of development. Between E12.5 andof E9.5 Vezf1 KO (/) and wild type (+/+) embryos. Vezf1/ embryos
d E) Whole mount immunohistochemistry for PECAM-1. The vasculature
appeared disorganized and less developed than in wild type controls (E).
mbryo. (C and F) Histological sections of same E9.5 embryos. Vezf1/
wheads). Note also the absence of the second aortic arch artery (arrow).
Table 2
Genotype of progeny from heterozygous Vezf1+/ intercrosses in a mixed
genetic backgrounda
Development
stage
No. of
embryos/pups
+/+ +/b /b
E10.5 14 3 7 4
E11.5 14 3 6 5
E12.5 44 16 26 (2) 2 (2)
E13.5 10 3 7 (1) 0
E14.5 35 10 20 5 (1)
E15.5 12 2 9 1 (1)
E16.5 2 1 1 0
P0 53 15 30 8 (stillborn)
P21 46 16 30 0
a Heterozygous F1 (129/Sv  C57BL/6) males were bred with outbred
CD-1 females, and offspring from F2 intercrosses were analyzed. Embryos
from embryonic stages E10.5 to E16.5 were genotyped by performing PCR
on genomic yolk sac DNA with primer pairs specific for the wild type and
targeted allele. Newborn (P0) and 3-week-old offspring (P21) genotyped by
performing PCR or Southern analysis on tail DNA.
b Numbers in parentheses represent embryos with vascular abnormalities
and hemorrhaging.
Fig. 3. Normal vascular development in Vezf1/ yolk sacs. (A and B)
Photomicrographs of whole-mount PECAM-1-stained E9.5 yolk sacs.
Vezf1/ yolk sacs (A) displayed a regular hierarchical vascular pattern that
is indistinguishable from that of wild type controls (B). (C and D) Sections
of the same PECAM-1-stained yolk sacs were counterstained with Nuclear
Fast Red. Inserts, details of yolk sacs at high magnification. Blood islands
are lined by PECAM-1-postive endothelial cells and filled with primitive,
nucleated erythrocytes (arrows). Vezf1/ yolk sacs (C) did not show any
signs of vascular disorganization or lesion. (D) Wild type control.
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intraembryonic bleeding and vascular malformations in the
head and trunk region, or they were resorbed (data not
shown). Vascular abnormalities were also observed in
heterozygous mutant embryos, albeit at a low frequency
(¨10%).
In summary, loss of Vezf1 function resulted in an
incompletely penetrant, haploinsufficient (autosomal) phe-
notype that was not caused by imprinting of the Vezf1 gene
or by generation of a dominant-negative allele.
Vascular remodeling defects and hemorrhaging in early
midgestation Vezf1/ embryos
The developing vasculature in overtly hemorrhaging
Vezf1 KO embryos and yolk sacs was examined in detail
by whole-mount immunostaining for the pan-endothelial
marker PECAM-1 (Baldwin et al., 1994) between E9.5 and
E10.5. Wild type and Vezf1+/ littermates exhibited a
complex, hierarchically organized vessel architecture
throughout the entire embryo. Vezf1/ mutant embryos
had normally formed major vessels, like dorsal aorta and
cardinal vein, but displayed prominent angiogenic remodel-
ing defects in the vascular networks of the head, the aortic
arch artery system, the heart, and the trunk. Thus, the
vasculature in head, neck, and back in homozygous mutant
Vezf1 embryos showed poor organization, was less
branched, and appeared underdeveloped (compare E9.5
Vezf1 KO and wild type embryos in Figs. 2B and E).
Furthermore, the first and second aortic arch arteries
frequently had failed to develop in Vezf1 KO embryos
(Figs. 2B and E). The remodeling defects were more
pronounced at E10.5, with an increased disorganization of
the trunk vessels and further deterioration of the arch
arteries (not shown). Histological analysis of parasagittalsections through PECAM-1-stained Vezf1/ embryos
revealed distinct sites of internal bleeding, typically in the
head, heart, and trunk, and confirmed the defects in the
aortic arch artery system. In the representative Vezf1 KO
embryo shown in Fig. 2C, the pericardial cavity was
enlarged and filled with blood, and an unusual number of
dilated, hemorrhaging vessels was detectable in the head. In
addition, the agenesis of the second aortic arch artery and a
rudimentary, lumen-less first aortic arch artery were
apparent.
In contrast to the observed abnormalities in the embryo
proper, no vascular defects were detected in the extra-
embryonic yolk sac, the initial site of endothelial and
hematopoietic differentiation. Whole-mount PECAM-1
staining of E9.5 and E10.5 yolk sacs from mutant embryos
showed a hierarchical vascular pattern that was indistin-
guishable from that of wild type controls (compare Figs. 3A
and B). Furthermore, PECAM-1-stained sections of mutant
yolk sacs displayed normally developed blood islands with
an outer layer of endothelial cells surrounding lumens that
are filled with primitive, nucleated erythrocytes, and regular
vascular patterning without any signs of lesions or
hemorrhaging (compare Figs. 3C and D).
Localized hemorrhaging in mutant Vezf1/ embryos at late
midgestation stages
A small fraction of homozygous mutant embryos
survived to day 16 of gestation. These late midgestation
Fig. 4. Hemorrhaging in E12.5 Vezf1/ embryos. (A and B) Whole-mount images of E12.5 Vezf1/ (A) and wild type (B) embryos. The E12.5 KO embryo
displayed hemorrhaging in the jugular region and subcapsular head mesenchyme (arrows). Parasagittal sections shown in C, E, G are derived from the Vezf1
KO embryo depicted in A, and sections shown in D, F, H are from the wild type embryo depicted in B. (C and D) Histological analysis of H&E-stained E12.5
Vezf1/ (C) and wild type (D) embryo. Arrows in C indicate sites of bleeding in the jugular region and the subcapsular head mesenchyme. (E and F)
Immunohistochemical PECAM-1 staining revealed overall normal vascular patterning in Vezf1/ (E) and wild type (F) embryos. (G and H)
Immunohistochemical SMa-actin staining demonstrated normal VSMC differentiation and recruitment in Vezf1 KO (G) and wild type (H) embryos. (I and
J) In transverse sections of anti-SMa-actin-stained embryos, the dorsal aorta is surrounded by several layers of VSMCs in Vezf1 KO (I) and wild type embryos
(J). (K and L) Wright–Giemsa staining of day 5 in vitro cultures of E12.5 fetal liver cells shows normal megakaryopoiesis in Vezf1/ embryos (K) as
compared to a wild type control embryo (L). Arrows indicate examples of megakaryocytes.
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plete penetrance (Table 1, Fig. 4A). Mutant E12.5 Vezf1/
embryos did not display grossly abnormal vascular pattern-
ing as visualized by PECAM-1 antibody staining of
parasagittal sections (Figs. 4E and F), consistent with
mostly normal angiogenic remodeling. In addition, develop-
ment of all organ systems, including heart, lung, and
placenta, appeared normal in H&E-stained histological
sections (Figs. 4C and D). However, localized hemorrhag-
ing, typically in the head and in the neck region, was
observed in these embryos, indicating the loss of vascular
integrity (see below). The representative E12.5 Vezf1/
embryo shown in Fig. 4C displays hemorrhaging in the
subcapsular mesenchyme of the head and in the jugular
region.
Normal vascular smooth muscle cell recruitment and
megakaryocyte development in Vezf1 KO embryos
Defects in the differentiation and/or recruitment of
VSMC or pericytes can result in destabilized, leaky blood
vessels and lead to lethal hemorrhage, as has been shown in
mice lacking Edg-1, LKLF, and PDGF-B (Kuo et al., 1997;
Lindahl et al., 1997; Liu et al., 2000). To investigate a
possible involvement of VSMC in the hemorrhaging
observed in mutant E12.5 Vezf1/ embryos, parasagittal
sections of embryos shown in Fig. 4 were immunostained
with anti-SM a-actin antibodies. In sections of Vezf1/ and
wild type control embryos, the dorsal aorta was completely
surrounded by VSMCs (Figs. 4G and H). Likewise, crosssections through the dorsal aorta (Figs. 4I and J) and
umbilical artery (not shown) of mutant embryos showed
several layers of VSMC.
Likewise, defects in the differentiation of megakaryo-
cytes can lead to defective platelet formation and control
of coagulation, resulting ultimately in lethal hemorrhaging
(Spyropoulos et al., 2000). To address whether megakar-
yocytopoiesis was affected in Vezf1 KO embryos, wild
type and Vezf1/ E12.5 fetal liver cells were cultured and
assayed in vitro for their differentiation potential into
megakaryocytes (Lecine et al., 1998). Normal megakar-
yocyte and proplatelet differentiation was apparent in day
5 in vitro cultures and Wright–Giemsa-stained cytospin
preparations derived from homozygous mutant fetal liver
cultures (Figs. 4K and L). Thus, defects in mural cell
recruitment and megakaryocyte differentiation can be
excluded as a cause for the vascular defects in E12.5
Vezf1/ embryos.
Vascular endothelial integrity is compromised in
hemorrhaging vessels
To understand the etiology of vascular leakage, we
performed ultrastructural analysis on hemorrhaging vessels
using transmission electron microscopy. Frontal sections
through heads of E11.5 mutant embryos in regions of visible
hemorrhaging revealed striking abnormalities (Fig. 5).
Leaky capillaries and small blood vessels were easily found
in the meningeal plexus. They displayed gaps between
endothelial cells (Figs. 5A, C, and E) or incomplete cell–
Fig. 6. Mutant vessels display abnormal expression of cell junction and
ECM proteins. Immunofluorescence studies and confocal microscopy of
dorsal regions from hemorrhaging E11.5 embryos and wild type littermate
controls. (A) Immunostaining with anti-ZO-1, anti-PECAM-1, and respec-
tive merged images at low magnification; yellow indicates co-localization.
(B) High magnification from same section. Note the dramatically reduced
and patchy pattern of anti-ZO-1 in mutant embryo. (C) High magnification
image of vessels stained with anti-VE-cadherin. Note reduced and patchy
expression. (D) Immunostaining with anti-Collagen IV, anti-PECAM-1, and
respective merged images at low magnification; yellow indicates co-
localization. Note the overall reduced pattern of anti-Collagen IV in mutant
embryo. A total of 3 mutant embryos and 2 wild type littermates from 2
E11.5 litters were examined.
Fig. 5. Hemorrhaging vessels display endothelial cell defects. Electron
microscopy photomicrographs of ultra-thin frontal sections of heads from
hemorrhaging E11.5 embryos (A–H) and wild type litter mate (I). A and B:
low (A) and high magnification images (B) of vessel in the choroid plexus;
arrow: gap in endothelial wall with extruding erythrocyte; arrowhead:
abnormal, filopodia-like projections on endothelial cells. C and D: same
animal as in A and B; arrow: break in endothelial wall; arrowhead:
fenestration in endothelial cell. E and F: same animal as in A and B; note
the large gaps between endothelial cells. G: small vessel from second
hemorrhaging embryo; note extravasation of single erythrocyte. H: same
animal as in A and B; small vessel embedded the neuronal tissue without
endothelial cell defect. I: wild type littermate control, capillary from
meningeal plexus with intact endothelium and intact cell junction (arrow).
A total of 3 mutant embryos and 2 wild type littermates from 2 E11.5 litters
were examined.
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erythrocytes could be detected at these gaps (Figs. 5A, B,
and G). The endothelial cells often appeared discontinuous
and fragmented (Figs. 5C and D) and had abnormal
filopodia-like protrusions (Figs. 5A and B) and excessive
fenestration (Fig. 5D). Under high magnification, an
incomplete basal lamina could be discerned (Fig. 5G). The
leaky vessels were localized immediately adjacent to the pia
mater or at more distal sites in the meningeal plexus. In
contrast, the small vessels embedded in the brain mesen-
chyme did not show signs of leakiness (Fig. 5H) and were
indistinguishable from capillaries of wild type littermates
(Fig. 5I).
We further examined the molecular basis for the
endothelial cell defects. Using co-immunostaining and
confocal imaging of sections from dorsal regions of
hemorrhaging embryos shown in Fig. 5, we investigated
the distribution of the tight junction protein ZO-1, the
intercellular adhesion protein VE-cadherin, the ECM proteinCollagen IV, and PECAM-1 (Fig. 6). In the endothelial wall
of mutant E11.5 embryos, fluorescent localization of both
anti-ZO-1 and anti-VE-cadherin had a disrupted pattern that
was significantly reduced when compared to that of wild
type littermates (Figs. 6A–C). Similarly, reduced levels of
Collagen IV deposition were detected in hemorrhaging
embryos (Fig. 6D). In contrast, localization of PECAM-1
was comparable between wild type and mutant capillaries.
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and disjointed Collagen IV deposition, were found in the
vessels and capillaries of E10.5 Vezf1/ embryos that did
not show hemorrhaging or overt vascular abnormalities
(Figs. 7A and B). These findings indicate that loss of Vezf1
function leads to defects in endothelial cell junctions and
extracellular matrix organization, and that these defects are
present before overt vascular abnormalities and hemorrhag-
ing become visible.
Vascular malformations and hemorrhaging in E13.5
embryos heterozygous for the targeted Vezf1 allele
Beginning at E12.5, hemorrhaging and edema, confined
mostly to the jugular region, became apparent in aboutFig. 7. Vezf1/ vessels are predisposed to loss of endothelial integrity. Immunof
Vezf1/ embryos and wild type littermate controls. No signs of hemorrhaging w
PECAM-1, respective merged images, and high magnification detail of boxed a
negative cells in the KO panel show continuous ZO-1 deposition. (B) Immunostai
high magnification detail of boxed area; yellow indicates co-localization. Spotty, d
of Collagen IV (B) were detected in Vezf1/ vessels and capillaries in the abse
pattern is similar to that detected in vessels of hemorrhaging E11.5 embryos (Fig. 620% of Vezf1+/ embryos (Table 1; compare Figs. 8A and
B). By E13.5, embryos appeared bloated and displayed
massive edema and bleeding in the back and neck region
(compare Figs. 8C and D). H&E-stained parasagittal
sections showed severe edema, with masses of loose
connective tissue and mesenchymal cells separated by
interstitial fluid, and subcutaneous bleeding in the back
and neck region (Figs. 8E and I). Furthermore, a dramatic
increase in vessel number was detected in close association
with the jugular sac (Figs. 8E and I) when compared to
wild type controls (Figs. 8F and J). PECAM-1 staining
revealed that Vezf1+/ embryos displayed an overall
normal looking vascular pattern and that hypervasculariza-
tion appeared confined to the jugular region (Fig. 8,
compare panels G, K, O to panels H, L, P). Vessels in theluorescence studies and confocal microscopy of dorsal regions from E10.5
ere detected in these embryos. (A) Immunostaining with anti-ZO-1, anti-
rea; yellow indicates co-localization. Note that non-endothelial, PECAM-
ning with anti-Collagen IV, anti-PECAM-1, respective merged images, and
iscontinuous ZO-1 staining (A) and thinner layers and disjointed deposition
nce of hemorrhaging or overt vascular abnormalities. Note that the overall
). Two E10.5 Vezf1/ embryos and 2 wild type littermates were examined.
Fig. 8. Hypervascularization, edema, and hemorrhaging in heterozygous Vezf1 embryos. (A–D) Photomicrographs of whole-mount E12.5 (A and B) and E13.5
(C and D) embryos. Hemorrhaging became apparent in the jugular region of a mutant E12.5 Vezf1+/ embryo (A). Affected E13.5 Vezf1+/ embryo (C)
displayed severe edema and hemorrhaging in the back and neck. (B and D) Wild type controls. (E and F) H&E staining of parasagittal sections of E13.5 Vezf1+/
(E) andwild type control (F) embryos. Severe edema in the back region, hypervascularization, and hemorrhaging are visible in the jugular area of the heterozygous
embryo (E). Boxed areas depict regions shown at higher magnification in panels I and J. (G and H) PECAM-1 staining of parasagittal sections close-by to those
shown in (E and F). PECAM-1 staining outlines the embryonic vasculature and shows that hypervascularization is confined to the neck and back region of the
mutant embryo (G). Boxed areas depict regions shown under higher magnification in panels K and O, and L and P, respectively. (I and J) High magnification
images of the jugular region from embryos shown in E and F. Arrowheads: abnormal vessels in jugular region; *jugular sac. (K–N) High magnification
photomicrographs of the jugular region of mutant Vezf1+/ embryo (K, M, N) and a wild type control (L) shown in G and H. Hypervascularization with abnormal
vessel morphology and loose surrounding connective tissue is visible in the jugular region (K and M). Lesions in the endothelial wall of small vessels and
erythrocytes leaking into the surrounding connective tissue (arrow) are detected in the neck region (N). (O and P) High magnification photomicrographs of the
dorsal region of mutant Vezf1+/ embryo (O) and wild type control (P) shown in G and H. The heterozygous mutant embryo (O) displayed tissue swelling and
masses of loose connective tissue.
Fig. 9. Quantitative morphometric analysis of the vasculature in the jugular
region of heterozygous and wild type E13.5 embryos. (A) Total vessel
number, (B) total vessel area. Three mutant Vezf1+/ and 3 wild type
embryos were examined. Mutant Vezf1+/ embryos show increased
vascularity in the jugular region, as measured by the extent of PECAM-
1-positive structures. Bars and errors indicate mean and SD values.
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anastomosing, and they were occasionally filled with blood
(Figs. 8K and M). Under high-power magnification, sites
of vascular lesions were visible with erythrocytes leaking
out into the surrounding mesenchymal tissue (Fig. 8N),
indicating loss of vessel integrity. Quantitative morpho-
metric analysis of PECAM-1-stained sections confirmed
that the overall vessel number and the total vessel area
were increased in the mid–back region of mutant
heterozygous embryos by approximately 50% and 130%,
respectively (Figs. 9A and B). Together, these results
suggest that localized endothelial hyperproliferation in the
jugular region leads to the formation of aberrant, dysfunc-
tional vessels in heterozygous embryos.
Fig. 10. Lymphatic hypervascularization in heterozygous mutant E13.5
embryos. (A–F) Parasagittal sections of an E13.5 Vezf1+/ embryo (A, C,
E) and wild type control embryo (B, D, F). Sections were immunostained
for the lymphatic markers VEGFR-3 (A and B) and LYVE-1 (C and D), and
for the VSMC marker SMa-actin (E and F). The hyperplastic vessels in the
jugular region of heterozygous E13.5 embryos stain positive for the
lymphatic markers VEGFR-3 (A) and LYVE-1 (C), but are negative for
SMa-actin (E). (G and H) High magnification of the jugular region from
images shown in (A and B). (I and J) High magnification of the jugular
region from images shown in (C and D). Jugular sacs in wild type control
are depicted by *. Examples of hyperplastic vessels in heterozygous
embryos are depicted by arrows in G and I. (K–N) Cryostat sections from a
mutant Vezf1+/ (K and L) embryo and a wild type littermate (M and N)
were double immunostained for PECAM-1 (K and M) and Prox1 (L and
N). Arrowheads depict Prox1-positive endothelial cells that appear
disorganized in heterozygous (L) but not in wild type control embryos (N).
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embryos
Hypervascularization in mutant Vezf1+/ embryos was
observed specifically in the jugular region, which consti-
tutes the first major site of lymphatic development (Sabin,
1909). Thus, lymphatic vessel formation in E13.5 wild type
and Vezf1+/ embryos was analyzed by immunostaining for
the lymphatic markers VEGFR-3 (Kaipainen et al., 1995),
LYVE-1 (Banerji et al., 1999), and Prox1 (Wigle and Oliver,
1999). In wild type embryos, expression of VEGFR-3 (Figs.
10B and H) and LYVE-1 (Figs. 10D and J) was detected in
the endothelium lining the jugular sac and in small
capillaries of the neck mesenchyme. In Vezf1+/ embryos,
in addition to these structures, the hyperplastic vessels in the
jugular region stained positive for the two lymphatic
markers (VEGFR-3, Fig. 10A and G; LYVE-1, Figs. 10C
and I), but did not express SMa-actin (Figs. 10E and F) or
desmin (not shown), indicating the absence of vessel-
associated vascular smooth muscle cells and pericytes,
respectively. Likewise, double immunofluorescence staining
for PECAM-1 and Prox1 revealed that the majority of the
aberrant vessels in the jugular region of heterozygous
embryos display lymphatic characteristics (Figs. 10K and
L), whereas in wild type controls only a subset of small
capillaries appear to be lymphatics (Figs. 10M and N). In
summary, our results indicate that the hyperplastic vessels in
Vezf1+/ embryos are of lymphatic nature and that loss of a
single Vezf1 allele leads to lymphatic hypervascularization
in the jugular region. Lymphatic defects in heterozygous
embryos could not be detected at later embryonic stages
(>E14.5) nor in juvenile or adult heterozygous Vezf1
offspring.
Gene expression analysis
Our results indicate that loss of Vezf1 function leads to
defects in endothelial cell proliferation, angiogenic remod-
eling, and maintenance of vascular integrity. A number of
factors have been implicated in these processes and shown
to display similar or partially overlapping mutant pheno-
types in gene inactivation studies (Carmeliet, 2000). To
assess if loss of Vezf1 function could be correlated with
changes in expression levels for any of these factors, semi-
quantitative reverse transcriptase polymerase chain reaction
(RT-PCR) analysis was performed on total RNA isolated
from E10.5 Vezf1/ embryos and wild type littermates.
Because of the incompletely penetrant phenotype, E10.5
Vezf1 KO embryos were selected that displayed clear signs
of hemorrhaging and vascular malformations. Expression of
the following groups of genes was examined (Fig. 11): (1)
VEGF-A, -C, and -D, and VEGFR-1, -2, and -3; (2)
Angiopoietin-1 and -2, their cognate tyrosine kinase
receptor Tie2, and the closely related orphan receptor Tie1
(Gale and Yancopoulos, 1999); (3) Notch1, Notch4, and its
ligand Dll4 that have been implicated in vascular morpho-genesis (Krebs et al., 2000); (4) EphrinB2 and its receptor
EphB4 that demarcate embryonic arterial versus venous
endothelium and are involved in vascular remodeling
(Adams et al., 1999; Krebs et al., 2000; Wang et al.,
1998); (5) LKLF, a Kru¨ppel-like zinc finger transcription
factor, Edg-1, the G-protein-coupled receptor for sphingo-
sine-1-phosphate, and Endoglin, an accessory TGF-h-
receptor, all of which show hemorrhaging KO phenotypes
Fig. 11. Gene expression analysis in Vezf1/ embryos. Semi-quantitative
RT-PCR (25, 30, and 35 cycles) using transcript-specific primers was
performed on total RNA isolated from E10.5 Vezf1/ and wild type
embryos. Primer pairs specific for Vezf1 and b-actin transcripts were
included in the analysis as controls, and to normalize for RNA amounts,
respectively. Vezf1 transcripts are absent in Vezf1/ embryos.
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podoplanin, two markers for lymphatic vessels (Wigle et al.,
2002) (Breiteneder-Geleff et al., 1999); (7) Tbx-1, a T-box
transcription factor required for development of the aortic
arch artery system in a gene-dosage dependent manner
(Lindsay et al., 2001); (8) VE-cadherin, an endothelial cell
adhesion molecule and regulator of endothelial cell survival
(Carmeliet et al., 1999); (9) Endothelin-1 (ET-1), a vaso-
constrictive signaling peptide. ET-1 inactivation leads to
malformations in the aortic arch system (Kurihara et al.,
1994), and the human ET-1 promoter is transactivated by
ZNF161/DB1 in vitro (Aitsebaomo et al., 2001). As
expected, Vezf1 transcripts were absent in E10.5 Vezf1/
embryos and present in wild type littermates. In contrast, no
differences in the expression of any of the candidate genes
examined were found between mutant and wild type
embryos (Fig. 11). In addition, the distribution of transcripts
for Flk-1, Flt-1, EphrinB2, Tie2, and ET-1 was analyzed by
RNA in situ hybridization on E11.5 embryos. No differ-
ences in the amount or spatial distribution of thesetranscripts between Vezf1/ and wild type embryos were
detected (data not shown). Thus, Vezf1 function is not
required for the expression of these candidate genes known
to regulate mammalian vasculogenesis and angiogenesis.Discussion
We report here that Vezf1 is essential for normal
development of the vascular system. Inactivation of Vezf1
leads to embryonic lethality, and mutant embryos display
specific defects during angiogenic remodeling, vascular
homeostasis, and lymphatic development. Analysis of the
homozygous mutant phenotype revealed that, while its
function is dispensable for the early stages of vascular
development, namely angioblast differentiation and the
formation of the primary vascular plexus, Vezf1 is required
for proper angiogenic remodeling and the maintenance of
vascular integrity. Homozygous mutant embryos can be
subdivided into two classes. Class 1 embryos display an
early phenotype that is characterized by defective angio-
genic remodeling, particularly in the developing vascula-
ture of the aortic arch system, the head and neck, and in
the intersomitic vessels, and by the loss of vascular
integrity leading to hemorrhaging. In contrast, class 2
embryos display apparently normal vascular patterning but
are subject to midgestation hemorrhaging. The manifes-
tation of vascular leakage in these later stage KO embryos
without concomitant vascular dysmorphogenesis suggests
that hemorrhaging in class 1 embryos is independent of the
angiogenic remodeling defects. This notion is further
supported by the fact that similar remodeling defects were
reported for the inactivation of Angiopoietin1, Tie2,
VEGFR-3, ephrinB2, EphB4, EphB2/B3, and Notch1/
Notch4, and that these mutants did not display any
vascular leakage (Adams et al., 1999; Detmar et al.,
1998; Gerety et al., 1999; Krebs et al., 2000; Sato et al.,
1995; Sun et al., 1996; Wang et al., 1998). Interestingly, in
those studies, abnormal vascular remodeling was also
observed in the extraembryonic yolk sac, whereas the yolk
sac vasculature appeared normal in Vezf1 KO embryos. A
plausible explanation is that Vezf1 acts in a combinatorial
fashion with other co-factors and therefore differentially
controls diverse developmental processes. We hypothesize
that Vezf1 function is dispensable for the yolk sac
vasculature or that redundant regular pathways can
compensate for loss of Vezf1.
Our studies strongly suggest that at the cellular level the
primary defect has its origin in the vascular endothelial cells
themselves. First, Vezf1 is expressed in endothelial cells
during embryogenesis (Xiong et al., 1999). Second and
most importantly, ultrastructural and immunohistochemistry
studies directly show loss of vascular wall integrity in
hemorrhaging vessels due to the apparent lack of proper
formation of inter-endothelial cell junctions and the inter-
action of endothelial cells with or the formation of the basal
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junctions and basal membrane were detected even before
the onset of the mutant phenotype. Thus, these endothelial
cell defects likely predispose vessels and capillaries to loss
of their integrity, possibly in a stochastic manner. Third, two
alternative causes were addressed in this study, namely
defects in VSMC differentiation and/or recruitment (Kuo et
al., 1997; Liu et al., 2000) and defective megakaryocyte
differentiation (Spyropoulos et al., 2000). However, both
processes were found to be normal in homozygous mutant
embryos. Fourth, our preliminary studies indicate that
embryonic lethality in Vezf1 KO embryos can be rescued
by endothelial overexpression of Vezf1 via a Tie2–Vezf1
transgene (Z. Zou, F. Kuhnert, and H. Stuhlmann, unpub-
lished). It is possible that additional cell-non-autonomous
effects by mesenchymal cells, vascular smooth muscle cells,
or pericytes contribute to the vascular phenotype as well.
Generation of Vezf1 conditional null alleles targeted to the
endothelial and smooth muscle cell lineages will provide
answers to this question.
The specific defects in cell–cell adhesion and tight
junction formation provide first insights into potential
molecular pathways in which Vezf1 participates. In this
context, it is of interest that our candidate gene approach has
not identified thus far in vivo downstream target genes. In
this study, the expression of a large canon of genes known to
regulate endothelial cell proliferation, angiogenic remodel-
ing, and the maintenance of vascular integrity was
examined. Loss of Vezf1 function could not be correlated
with changes in the expression levels for any of these genes.
In a recent study, in vitro binding and transactivation of the
human ET-1 promoter by ZNF161/DB1, the human
ortholog of Vezf1, was demonstrated (Aitsebaomo et al.,
2001). Interestingly, mice deficient for ET-1 display defects
in the aortic arch artery system (Kurihara et al., 1994, 1995).
However, no effects of Vezf1 inactivation on ET-1 transcript
levels and its spatial distribution could be detected.
Furthermore, during the preparation of the manuscript, a
report by Miyashita et al. identified the microtubule-
destabilizing protein stathmin/OP18 as a potential in vitro
target of VEZF1 (Miyashita et al., 2004). A microarray
expression profiling approach using Vezf1 KO and wild
type endothelial cells should be instrumental in identifying
Vezf1 target genes and thus provide further insights into the
molecular mechanisms that underlie Vezf1 function.
Our results indicate that Vezf1 acts in a closely regulated,
dose-dependent manner during vascular development.
Approximately 20% of heterozygous embryos displayed
lymphatic hypervascularization in the jugular region,
associated with edema and hemorrhaging. This incom-
pletely penetrant, haploinsufficient (autosomal) phenotype
is caused neither by imprinting of the residual wild type
allele, nor by the generation of a dominant-negative VEZF1
mutant peptide. Several other examples of haploinsuffi-
ciency in genes crucial for vascular development have been
reported; these include VEGF-A, TGF-h, the T-box tran-scription factor Tbx-1, and the Notch ligand Delta4
(Carmeliet et al., 1996b; Dickson et al., 1995; Duarte et
al., 2004; Ferrara et al., 1996; Krebs et al., 2004; Lindsay et
al., 2001). However, Vezf1 appears to be the only vascular
haploinsufficiency gene that affects lymphatic development.
Our results indicate that Vezf1 is involved in the
regulation of early events of lymphangiogenesis, as lym-
phatic hypervascularization is specifically observed in the
jugular region, the first site of lymphatic sprouting from the
venous system. The increased vascularity suggests lym-
phatic endothelial hyperproliferation or increased lymphatic
endothelial differentiation as a plausible mechanism for the
observed vascular hyperplasia and identifies Vezf1 as a
negative regulator of lymphatic development. Support for
this notion comes from recent studies in which knock-down
of the human ortholog DB1 in primary endothelial cells
leads to an increase in lymphatic phenotype and gene
expression (I. Adini and L. Benjamin, personal communi-
cation). A low incidence of vascular defects in the jugular
region of homozygous mutant embryos, albeit less pro-
nounced than in affected heterozygotes (Fig. 4C), could be
detected (4 out of 17 Vezf1/ embryos obtained between
E12.5 and E14.5). We surmise that the early lethality in
Vezf1/ embryos in combination with the apparent genetic
background susceptibility of the lymphatic phenotype
precluded a more robust detection (both in frequency and
severity) in homozygous mutant embryos.
The lymphatic nature of the hyperplastic vessels appears
to conflict with the fact that many of these contain red blood
cells. However, it has been reported that lymphatic
capillaries may contain stagnant blood, which is removed
into the venous circulation once the lymphatic system
becomes functional (Clark, 1912; Lewis, 1905; Miller,
1913). Alternatively, separation of the emerging lymphatic
vessels from the blood vasculature may be defective in the
mutant mice, similar to the phenotype recently reported for
the inactivation of the hematopoietic signaling proteins
SLP-76 and Syk (Abtahian et al., 2003). Of interest, severe
edema and hemorrhaging were not detected at later
embryonic stages, in other regions of embryonic lymphan-
giogenesis, or in heterozygous juvenile or adult offspring.
We therefore hypothesize that a specific window, both
temporal and spatial, exists during which lymphangio-
genesis is susceptible to loss of Vezf1.
Lymphatic development is initiated by budding and
sprouting of Prox1 and LYVE-1-positive cells from the
anterior cardinal vein at around E10 (Oliver and Harvey,
2002). The nascent lymphatic endothelial cells migrate
dorsoanteriorly to form the jugular lymph sacs. Prox1
activity is required for maintaining sprouting of lymphatic
endothelial cells, and loss of Prox1 function results in the
arrest of lymphatic development (Wigle and Oliver, 1999;
Wigle et al., 2002). Careful etiological analysis will be
necessary to further elucidate the mechanism underlying the
lymphatic phenotype in Vezf1+/ embryos. For example, it
will be important to examine if overexpression of Vezf1 in
F. Kuhnert et al. / Developmental Biology 283 (2005) 140–156154blood endothelial cells antagonizes Prox1 function, and if
forced Vezf1 expression in lymphatic endothelial cells has
anti-proliferative or anti-differentiation effects.
The haploinsufficient lymphatic phenotype observed in
E13.5 Vezf1+/ embryos is reminiscent of a human
malformation syndrome, cystic hygroma. Cystic hygromas
are congenital malformations of the lymphatic system that
occur at sites of lymphatic-venous connection, most
commonly in the posterior neck (Gallagher et al., 1999).
Typically, cystic hygromas develop late in the first trimester,
either as a consequence of failure of the lymphatic vessels to
connect to the venous system, leading to the accumulation
of fluid in dilated lymphatics and to progressive lymphe-
dema, or due to abnormal budding of lymphatic endothe-
lium (Edwards and Graham, 1990). Although cystic
hygromas are frequently associated with other malformation
syndromes characterized by chromosomal abnormalities,
such as Turner syndrome or Trisomy 21, fetal nuchal cystic
hygromas with normal karyotypes have been reported
(Marchese et al., 1985). It will be important to examine if
haploinsufficiency of the human ortholog ZNF161/DB1 is
associated with this human syndrome. Moreover, it will be
interesting to determine if loss of ZNF161/DB1 function can
be correlated with other known hyperplastic conditions
thought to arise by excessive proliferation of lymphatic
endothelial cells, such as lymphangioma, lymphangiosar-
coma, and Kaposi’s sarcoma (Witte et al., 1997).
In summary, our results identify Vezf1 as a gene whose
function is crucial for the normal development of blood and
lymphatic vasculature in mice in a dosage-dependent
manner. At the cellular level, Vezf1 acts cell-autonomously
in endothelial cells and affects integrity and proliferation of
the developing vessels. Vezf1 might participate in yet
unknown pathways that affect vascular differentiation and
endothelial proliferation. To elucidate these molecular
pathways, it will be important to identify genes that function
in the same transcriptional regulatory circuits as VEZF1.Acknowledgments
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